# Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

> **NCT02111499** · PHASE1,PHASE2 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 18 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LAS41004-IMP1
- **DRUG:** LAS41004 IMP2
- **DRUG:** LAS41004 IMP3
- **DRUG:** LAS41004 IMP4
- **DRUG:** LAS41004 IMP6
- **DRUG:** LAS41004 IMP5

## Key facts

- **NCT ID:** NCT02111499
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111499, "Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02111499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*